By signing up Takeda Pharmaceutical to co-develop and market jointly one of its proprietary immune response modifiers (IRMs) for high-risk human papillomavirus (HPV) infection and cervical dysplasia, 3M is aiming to commercialise a follow-up to the successful Aldara#174; Cream 5% (imiquimod). Takeda's motives are similarly forward thinking.